Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY10 | O00398 | 5/20 | 0.36 |
| ▸ | GPR34 | Q9UPC5 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | DGKA | P23743 | 1/20 | 0.34 |
| ▸ | ENPP2 | Q13822 | 5/20 | 0.34 |
| ▸ | LPAR6 | P43657 | 1/20 | 0.34 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.34 |
| ▸ | LPAR4 | Q99677 | 1/20 | 0.34 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.34 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.34 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.34 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26424122 | 1.00 | P2RY10 (0.36) | P2RY10GPR34CYP3A4DGKAENPP2 | |
| SCHEMBL26424317 | 0.87 | CETP (0.45) | P2RY10CYP3A4LPAR1LPAR3ALDH1A1 | |
| SCHEMBL26424133 | 0.83 | FOLH1 (0.39) | P2RY10GPR34CYP3A4ALDH1A1 | |
| SCHEMBL21804584 | 0.77 | DGKA (0.49) | P2RY10GPR34DGKAENPP2LPAR6 | |
| SCHEMBL25231423 | 0.74 | DGKA (0.48) | CYP3A4DGKAALDH1A1 | |
| SCHEMBL16542326 | 0.73 | HTR2C (0.37) | P2RY10GPR34DGKAPLA2G2AALDH1A1 | |
| SCHEMBL22828741 | 0.73 | LMNA (0.39) | CYP3A4ALDH1A1 | |
| SCHEMBL23923374 | 0.72 | HTR2C (0.39) | P2RY10GPR34DGKAENPP2LPAR6 | |
| SCHEMBL26108904 | 0.71 | DGKA (0.64) | CYP3A4DGKAALDH1A1 | |
| SCHEMBL2239484 | 0.70 | DGKA (0.48) | P2RY10GPR34CYP3A4DGKALPAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230128984-A1 | BILE ACID-GCPII INHIBITOR CONJUGATES TO TREAT INFLAMMATORY DISEASES, INCLUDING INFLAMMATORY BOWEL DISEASE (IBD) | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY AS CR V.V.I. (CZ) | 2023-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230128984-A1 | BILE ACID-GCPII INHIBITOR CONJUGATES TO TREAT INFLAMMATORY DISEASES, INCLUDING INFLAMMATORY BOWEL DISEASE (IBD) | SLC10A2, GPBAR1, NR1H4 | P2RY10 826/4885GPR34 1028/4885CYP3A4 1476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.